Schizophrenia

Kaleidoscope.

Tracy DK, Joyce DW, Shergill SS. Kaleidoscope. Br J Psychiatry. 2014;205(6):505-6. DOI: 10.1192/bjp.205.6.505. PubMed PMID: 25452611.

The 16p11.2 locus modulates brain structures common to autism, schizophrenia and obesity.

Maillard AM, Ruef A, Pizzagalli F, Migliavacca E, Hippolyte L, Adaszewski S, et al. The 16p11.2 locus modulates brain structures common to autism, schizophrenia and obesity. Mol Psychiatry. 2015;20(1):140-7. DOI: 10.1038/mp.2014.145. PubMed PMID: 25421402.

Treatment resistance and other complicating factors in the management of schizophrenia.

Strassnig MT, Harvey PD. Treatment resistance and other complicating factors in the management of schizophrenia. CNS Spectr. 2014;19 Suppl 1:16-23; quiz 13-5, 24. DOI: 10.1017/S1092852914000571. PubMed PMID: 25410772.

Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia.

Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014;19 Suppl 1:38-52; quiz 35-7, 53. DOI: 10.1017/S1092852914000601. PubMed PMID: 25403863.

Relationship between metabolic syndrome and psychiatric disorders in patients with bipolar disorder or schizophrenia.

Kawada T. Relationship between metabolic syndrome and psychiatric disorders in patients with bipolar disorder or schizophrenia. Bipolar Disord. 2015;17(2):233-4. DOI: 10.1111/bdi.12279. PubMed PMID: 25400223.

Schizophrenia genetics: emerging themes for a complex disorder.

Kavanagh DH, Tansey KE, O'Donovan MC, Owen MJ. Schizophrenia genetics: emerging themes for a complex disorder. Mol Psychiatry. 2015;20(1):72-6. DOI: 10.1038/mp.2014.148. PubMed PMID: 25385368.

The cost of relapse and the predictors of relapse in the treatment of schizophrenia.

Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. Bmc Psychiatry. 2010;10:2. DOI: 10.1186/1471-244X-10-2. PubMed PMID: 20059765; PubMed Central PMCID: PMC2817695.

Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system.

Dassa D, Boyer L, Benoit M, Bourcet S, Raymondet P, Bottai T. Factors associated with medication non-adherence in patients suffering from schizophrenia: a cross-sectional study in a universal coverage health-care system. Aust N Z J Psychiatry. 2010;44(10):921-8. DOI: 10.3109/00048674.2010.493503. PubMed PMID: 20932206.

Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy.

Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol. 1998;8(1):55-66. PubMed PMID: 9452941.

Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies.

Kane JM. Strategies for improving compliance in treatment of schizophrenia by using a long-acting formulation of an antipsychotic: clinical studies. J Clin Psychiatry. 2003;64 Suppl 16:34-40. PubMed PMID: 14680417.